A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, STUDY OF THE EFFICACY AND SAFETY OF TOFACITINIB IN SUBJECTS WITH ACTIVE ANKYLOSING SPONDYLITIS (AS)
Status: Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 12 Nov 2019
Price : $35 *
At a glance
- Drugs Tofacitinib (Primary)
- Indications Ankylosing spondylitis
- Focus Registrational; Therapeutic Use
- Sponsors Pfizer
- 20 Oct 2019 Planned primary completion date changed from 19 Dec 2019 to 26 Dec 2019.
- 18 Sep 2019 Planned primary completion date changed from 10 Jan 2020 to 19 Dec 2019.
- 18 Sep 2019 Status changed from recruiting to active, no longer recruiting.